Literature DB >> 10422827

Long-range effects in protein--ligand interactions mediate peptide specificity in the human major histocompatibilty antigen HLA-B27 (B*2701).

S Krebs1, D Rognan, J A López de Castro.   

Abstract

B*2701 differs from all other HLA-B27 subtypes of known peptide specificity in that, among its natural peptide ligands, arginine is not the only allowed residue at peptide position 2. Indeed, B*2701 is unique in binding many peptides with Gln2 in vivo. However, the mutation (Asp74Tyr) responsible for altered selectivity is far away from the B pocket of the peptide binding site to which Gln/Arg2 binds. Here, we present a model that explains this effect. It is proposed that a new rotameric state of the conserved Lys70 is responsible for the unique B*2701 binding motif. This side chain should be either kept away from pocket B through its interaction with Asp74 in most HLA-B27 subtypes, or switched to this pocket if residue 74 is Tyr as in B*2701. Involvement of Lys70 in pocket B would thus allow binding of peptides with Gln2. Binding of Arg2-containing peptides to B*2701 is also possible because Lys70 could adopt another conformation, H-bonded to Asn97, which preserves the same binding mode of Arg2 as in B*2705. This model was experimentally validated by mutating Lys70 into Ala in B*2701. Edman sequencing of the B*2701(K70A) peptide pool showed only Arg2, characteristic of HLA-B27-bound peptides, and no evidence for Gln2. This supports the computational model and demonstrates that allowance of B*2701 for peptides with Gln2 is due to the long-range effect of the polymorphic residue 74 of HLA-B27, by inducing a conformational switch of the conserved Lys70.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10422827      PMCID: PMC2144368          DOI: 10.1110/ps.8.7.1393

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  45 in total

1.  The three-dimensional structure of HLA-B27 at 2.1 A resolution suggests a general mechanism for tight peptide binding to MHC.

Authors:  D R Madden; J C Gorga; J L Strominger; D C Wiley
Journal:  Cell       Date:  1992-09-18       Impact factor: 41.582

2.  Identification of self peptides bound to purified HLA-B27.

Authors:  T S Jardetzky; W S Lane; R A Robinson; D R Madden; D C Wiley
Journal:  Nature       Date:  1991-09-26       Impact factor: 49.962

3.  Novel HY peptide antigens presented by HLA-B27.

Authors:  W A Simmons; S G Summerfield; D C Roopenian; C A Slaughter; A R Zuberi; S J Gaskell; R S Bordoli; J Hoyes; C R Moomaw; R A Colbert; L Y Leong; G W Butcher; R E Hammer; J D Taurog
Journal:  J Immunol       Date:  1997-09-15       Impact factor: 5.422

4.  HLA-B27 subtypes positively and negatively associated with spondyloarthropathy.

Authors:  A R Nasution; A Mardjuadi; S Kunmartini; N G Suryadhana; B Setyohadi; D Sudarsono; N M Lardy; T E Feltkamp
Journal:  J Rheumatol       Date:  1997-06       Impact factor: 4.666

5.  Bound water structure and polymorphic amino acids act together to allow the binding of different peptides to MHC class I HLA-B53.

Authors:  K J Smith; S W Reid; K Harlos; A J McMichael; D I Stuart; J I Bell; E Y Jones
Journal:  Immunity       Date:  1996-03       Impact factor: 31.745

6.  HLA-B27 subtypes in Asian patients with ankylosing spondylitis. Evidence for new associations.

Authors:  C López-Larrea; K Sujirachato; N K Mehra; P Chiewsilp; D Isarangkura; U Kanga; O Dominguez; E Coto; M Penã; F Setién
Journal:  Tissue Antigens       Date:  1995-03

7.  Differences in endogenous peptides presented by HLA-B*2705 and B*2703 allelic variants. Implications for susceptibility to spondylarthropathies.

Authors:  F Boisgérault; V Tieng; M C Stolzenberg; N Dulphy; I Khalil; R Tamouza; D Charron; A Toubert
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

8.  Binding of peptides naturally presented by HLA-B27 to the differentially disease-associated B*2704 and B*2706 subtypes, and to mutants mimicking their polymorphism.

Authors:  B Galocha; J R Lamas; J A Villadangos; J P Albar; J A López de Castro
Journal:  Tissue Antigens       Date:  1996-11

9.  Pocket mutations of HLA-B27 show that anchor residues act cumulatively to stabilize peptide binding.

Authors:  K C Parker; W E Biddison; J E Coligan
Journal:  Biochemistry       Date:  1994-06-21       Impact factor: 3.162

10.  The specificity of peptides bound to human histocompatibility leukocyte antigen (HLA)-B27 influences the prevalence of arthritis in HLA-B27 transgenic rats.

Authors:  M Zhou; A Sayad; W A Simmons; R C Jones; S D Maika; N Satumtira; M L Dorris; S J Gaskell; R S Bordoli; R B Sartor; C A Slaughter; J A Richardson; R E Hammer; J D Taurog
Journal:  J Exp Med       Date:  1998-09-07       Impact factor: 14.307

View more
  2 in total

Review 1.  A molecular insight on the association of HLA-B27 with spondyloarthropathies.

Authors:  M Martí; I Alvarez; J A López de Castro
Journal:  Curr Rheumatol Rep       Date:  1999-10       Impact factor: 4.592

Review 2.  T-cell studies in the spondyloarthropathies.

Authors:  E Märker-Hermann; P Schwab
Journal:  Curr Rheumatol Rep       Date:  2000-08       Impact factor: 4.592

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.